Pipeline

Home
Company Info
- Management Team
- Bor-Wen Wu, PhD MBA
- John Bomalaski, MD
- Amanda Johnston, PhD
- Wei He, PhD
- Jim Thomson, PhD
- Archie Prestayko, PhD
- W. Jenny Kung, PhD
- Advisory Board
- George Demetri, MD
- Robert C. Jackson, PhD
- Jedd D. Wolchok, MD PhD
- Subsidiaries
- Polaris Pharmaceuticals
- Polaris Group Affiliates
- TDW Pharmaceuticals
- DRX Pharmaceuticals
- DRX (Shanghai)
Pipeline
Collaborations
Literature
- Polaris & Collaborators
- ADI-PEG 20 (oncology)
- TNF-PEG 20:
- CK2 inhibitor:
- ADI-PEG 20 (antiviral):
- Related Publications
- ADI general:
- ADI (oncology) renal cell carcinoma:
- ADI (oncology) head and neck cancer:
- ADI (oncology) combination therapy:
- TNF cancer treatment:
- CK2 inhibitor:
Company News
Contact

Progress Chart

¹ Combination Study with Docetaxel

² Combination Study with Cisplatin

³ ADI-PEG20 Study Sponsored by Ludwig Institute for Cancer Research

⁴ ADI-PEG20 Study Sponsored by Barts Cancer Institute, Queen Mary University of London